Sumitomo Pharma, Last Fiscal Year Net Income Revised Upward by 48%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon Apr 28, 2025 5:00 pm JST Revision

4506 Sumitomo Pharma Co., Ltd. 【IFRS】

Guidance Update Report

Sumitomo Pharma Co., Ltd. <4506> [TSE Prime] announced a performance revision after the market closed on April 28th (17:00). The consolidated net income for the fiscal year ending March 2025 has been revised upward 47.5%, from the previous forecast of 16 billion yen to 23.6 billion yen (compared to a loss of 314 billion yen in the previous period).

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated net income is expected to increase 15.8%, from the previous forecast of 48.2 billion yen to 55.8 billion yen (compared to a loss of 247 billion yen in the same period of the previous year).

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	200,251	29,179	ー	48,229	121.4	0	Jan 31, 2025	IFRS
Oct - Mar, 2024 New	218,051	36,979	ー	55,829	140.7	0	Apr 28, 2025	IFRS
Revision Rate	+8.9%	+26.7%	－	+15.8%	+15.9%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	381,000	21,000	ー	16,000	40.3	0	Jan 31, 2025	IFRS
Mar, 2025 New	398,800	28,800	ー	23,600	59.5	0	Apr 28, 2025	IFRS
Revision Rate	+4.7%	+37.1%	－	+47.5%	+47.7%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	161,916	-268,361	-266,987	-247,228	-622.3	0	May 14, 2024	IFRS
Oct - Mar, 2024 Guidance	218,051	36,979	ー	55,829	140.7	0	Apr 28, 2025	IFRS
YoY	+34.7%	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	555,544	-76,979	-47,920	-74,512	-187.6	21	May 15, 2023	IFRS
Mar, 2024	314,558	-354,859	-323,114	-314,969	-792.8	0	May 14, 2024	IFRS
Mar, 2025 Guidance	398,800	28,800	ー	23,600	59.5	0	Apr 28, 2025	IFRS
YoY	+26.8%	－	－	－	－